| DIGN Stock | | | SEK 1.14 0.02 1.72% |
CEO
Mr. William Cronin was Member of the Board of Directors of Dignitana AB since August 13, 2015 and he was appointed Chief Executive Officer of the Company, effective as of January 27, 2018. He has previously been Chief Executive Officer of Dignitana Inc. within the Company since November 8, 2016. Before bringing experience to the medical technology field, Bill Cronin began his career in finance, starting with Shearson Lehman Brothers in New York in 1987 and then moving to Dallas in 1992 to work with Capital Institutional Services as their Head of International Sales and Trading. After leaving CIS in 1999, Mr. Cronin became President of Direct Trading Institutional, an early pioneer in high speed electronic trading, which was ultimately sold to Knight Capital Group . Mr. Cronin became involved with scalp cooling after his wifes diagnosis with breast cancer in 2011. After success with scalp cooling, together they founded Chemo Cold Caps, LLC, one of the USbased providers of manual scalp cooling solutions to patients since 2018.
| Age | 58 |
| Tenure | 6 years |
| Phone | 46 46 16 30 90 |
| Web | https://dignitana.com |
Cronin began working with Dignitana in 2014 as the Company’s clinical trial was being completed, becoming COO of the US subsidiary after FDA clearance in 2015. He was appointed CEO of Dignitana Inc. in 2016 and of AB in November 2017. He also serves as CEO of Dignitana S.r.l, which was registered in Italy in 2018. A native of New Jersey, Bill is a graduate of Muhlenberg College in Pennsylvania and has a Masters in Business Administration in Finance from the University of Texas Dallas. His current Board positions include Chairman, C3 Device Partners.
Dignitana Management Efficiency
The company has return on total asset
(ROA) of
(0.2464) % which means that it has lost $0.2464 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.7786) %, meaning that it generated substantial loss on money invested by shareholders. Dignitana's management efficiency ratios could be used to measure how well Dignitana manages its routine affairs as well as how well it operates its assets and liabilities.
Dignitana AB has accumulated 15.83
M in total debt with debt to equity ratio
(D/E) of 0.27, which may suggest the company is not taking enough advantage from borrowing. Dignitana AB has a current ratio of 2.24, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Dignitana until it has trouble settling it off, either with new capital or with free cash flow. So, Dignitana's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dignitana AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dignitana to invest in growth at high rates of return. When we think about Dignitana's use of debt, we should always consider it together with cash and equity.
Similar Executives
Dignitana AB , a medical technology company, develops, produces, and markets medical cooling devices primarily in the United States. Dignitana AB was incorporated in 2007 is headquartered in Lund, Sweden. Dignitana is traded on Stockholm Stock Exchange in Sweden. Dignitana AB (DIGN) is traded on Stockholm Exchange in Sweden and employs 25 people.
Management Performance
Dignitana AB Leadership Team
Elected by the shareholders, the Dignitana's board of directors comprises two types of representatives: Dignitana inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dignitana. The board's role is to monitor Dignitana's management team and ensure that shareholders' interests are well served. Dignitana's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dignitana's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James McKinney, President, Chief Operating Officer | |
| Mikael Wahlgren, Deputy Managing Director, Director | |
| Anette Cronstroem, Ex Officer | |
| Karin Liwendahl, Chief Financial Officer | |
| Ulf Jonsson, Chief Officer | |
| Mary Hatcher, Chief Financial Officer | |
| Josephine Divers, Vice President Clinical Oncology Services | |
| Greg Dingizian, Director | |
| Jonas Sohlman, Interim Chief Financial Officer | |
| Darren Henderson, Vice President Quality and Regulatory Affairs | |
| Johan Johansson, RD Operations | |
| Pontus Kristiansson, Director | |
| Jane Wall, Director Services | |
| Thomas Joyce, Ex Officer | |
| Ingrid Heiman, Director | |
| Bill Leuchten, Group Vice President Sales | |
| Catarina Lwenadler, Chief Officer | |
| Thomas Kelly, Chairman of the Board | |
| Cameron OMara, Exec Sales | |
| Christian Lindgren, VP Director | |
| William Cronin, Chief Executive Officer, Director | |
| Melissa Bourestom, Vice President Marketing, Talent and Investor Relations | |
Dignitana Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dignitana a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Dignitana Stock Analysis
When running Dignitana's price analysis, check to
measure Dignitana's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dignitana is operating at the current time. Most of Dignitana's value examination focuses on studying past and present price action to
predict the probability of Dignitana's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dignitana's price. Additionally, you may evaluate how the addition of Dignitana to your portfolios can decrease your overall portfolio volatility.